Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer

NCT01671774 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

CLDN18.2-positive Gastric Adenocarcinoma
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
CLDN18.2-positive Adenocarcinoma of Esophagus

Interventions

DRUG: IMAB362
DRUG: Zoledronic acid
DRUG: Interleukin-2 (1 million IU)
DRUG: Interleukin-2 (3 million IU)

Sponsor

Astellas Pharma Global Development, Inc.